[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sciton\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100545987","laser-treatment-for-lichen-sclerosus-100545987",false,"NCT06389071","Laser Treatment for Lichen Sclerosus","Safety and Efficacy of Ablative Fractional 2940 nm Laser Treatment for Lichen Sclerosus Lesion","Inclusion Criteria:\n\n* Female aged 18 years or older\n* Biopsy-proven vulvar lichen sclerosus lesion\n* Experiencing one or more of the following symptoms of LS:\n\n  1. Dryness\n  2. Itching\n  3. Burning\n  4. Bleeding\n  5. Blistering\n  6. Soreness\n  7. Easily bruises\n  8. Easily tears\n  9. Ulcerated lesions\n  10. Painful intercourse\n* Negative urine pregnancy test if subject is of childbearing potential before enrollment\n* Absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and STI\n* Ability to understand and sign informed consent, questionnaires, and all investigation requirements\n* Willing to consent to clinical photographs of the treatment area\n* Willing to consent to ultrasound images of the treatment area\n* Willing and able to logistically follow schedule of treatments and follow-up visits\n\nExclusion Criteria:\n\n* Pregnancy, less than 3 months postpartum, or planning to become pregnant during the investigation to protect integrity of the data\n* Is a nursing mother\n* History of uncontrolled malignant disease\n* Active urogenital infection or chronic infection (i.e., candida, herpes, herpes simplex, bacterial vaginosis, trichomoniasis, or other infection)\n* Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich syndrome)\n* Subjects with genital skin disease, psoriasis due to risk of koeberizing\n* Subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin\n* Known allergy or intolerance to local anesthesia\n* Known history of connective tissue disease\n* Known propensity for keloid formations\n* Known medical condition that may affect wound healing\n* Any reason that the investigator deems prohibits participation in the investigation",true,"FEMALE","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Fractional ablative laser treatment for Lichen Sclerosus lesion",[27],"Lichen Sclerosus Lesion","RECRUITING","2026-04-21",{"date":31,"type":32},"2026-04-23","ACTUAL",{"date":34,"type":32},"2024-03-01",{"date":36,"type":21},"2027-12-30",{"name":38,"class":39},"Sciton","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":60,"locationsCount":40},"100496950","evaluation-of-fractional-ablative-laser-treatment-for-skin-conditions-100496950","NCT05750901","Evaluation of Fractional Ablative Laser Treatment for Skin Conditions","Pilot Evaluation of Fractional Ablative Laser Treatment for Skin Laxity and Tightening","Inclusion Criteria:\n\n1. Male or female subjects aged 18-85 years\n2. Fitzpatrick skin type I-VI\n3. Has visible skin laxity in the treatment region or has a scar\n4. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (Applicable to female subjects only)\n5. Willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes\n6. Subject must be able to read, understand and sign Informed Consent Form in English\n7. Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions\n\nExclusion Criteria:\n\n1. Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.\n2. Any type of prior cosmetic treatment to the target area at physicians' discretion\n3. History of malignant tumors in the target area.\n4. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles.\n5. Pregnant and\u002For breastfeeding (Applicable to females only)\n6. Having an infection, dermatitis or a rash in the treatment area.\n7. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders.\n8. Suffering from coagulation disorders or taking prescription anticoagulation medications.\n9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.\n10. History of immunosuppression\u002Fimmune deficiency disorders or currently using immunosuppressive medications.\n11. History of vitiligo, eczema, or psoriasis.\n12. History of disease stimulated by heat, such as recurrent herpes simplex and\u002For herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.\n13. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.\n14. Current smoker or history of smoking within 6 months of study participation.\n15. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study","ALL","85 Years",{"count":51,"type":21},1000,[24],"Evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening",[55],"Skin Laxity",{"date":31,"type":32},{"date":58,"type":32},"2022-11-01",{"date":36,"type":21},{"name":38,"class":39},""]